BCTXW
BriaCell Therapeutics Corp. Warrant
即時價格
價格圖表
關鍵指標
市場指標
開盤
$0.000
最高
$0.000
最低
$0.000
交易量
0.02M
公司基本面
交易統計
相關新聞
BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26
PHILADELPHIA and VANCOUVER, British Columbia, June 04, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)), (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company
BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025
Three BriaCell posters and one publish-only abstract highlight robust clinical data from Bria-IMT™ and Bria-OTS™ studies in metastatic breast cancer (MBC)Median Overall Survival of 17.3 months in Phase 2
BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor
Bria-OTS has cleared its safety evaluation in the Phase 1/2 study monotherapy dosage settingPhase 1/2 study has now transitioned to dosing patients in combination with checkpoint inhibitor in metastatic breast cancer
BriaCell CEO Letter to Shareholders
Repeated positive recommendation from Data Safety Monitoring Board ("DSMB") of pivotal Phase 3 study for lead clinical candidate Bria-IMT™ in combination with checkpoint inhibitorBria-IMT has received Fast Track
